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Background-—Animal study results point to oxidative stress as a key mechanism triggering postoperative atrial fibrillation (PoAF),
yet the extent to which specific biomarkers of oxidative stress might relate to PoAF risk in humans remains speculative.
Methods and Results-—We assessed the association of validated, fatty acid–derived oxidative stress biomarkers (F2-isoprostanes,
isofurans, and F3-isoprostanes) in plasma and urine, with incident PoAF among 551 cardiac surgery patients. Biomarkers were
measured at enrollment, the end of surgery, and postoperative day 2. PoAF lasting ≥30 seconds was confirmed with rhythm strip
or electrocardiography and centrally adjudicated. Outcomes were assessed until hospital discharge or postoperative day 10,
whichever occurred first. Urine level of each oxidative stress biomarker rose at the end of surgery (2- to 3-fold over baseline,
P<0.001) and subsequently declined to concentrations comparable to baseline by postoperative day 2. In contrast, plasma
concentrations remained relatively stable throughout the perioperative course. Urine F2-isoprostanes and isofurans at the end of
surgery were 20% and 50% higher in subjects who developed PoAF (P≤0.009). While baseline biomarker levels did not associate
significantly with PoAF, end of surgery and postoperative day 2 isoprostanes and isofurans demonstrated relatively linear
associations with PoAF. For example, the end of surgery extreme quartile multivariate adjusted OR (95% CI) for urine isofurans and
F3-isoprostanes were 1.95 (1.05 to 3.62; P for trend=0.01) and 2.10 (1.04 to 2.25, P for trend=0.04), respectively. The
associations of biomarkers with PoAF varied little by demographics, surgery type, and medication use (P≥0.29 for each).
Conclusions-—These novel results add to accumulating evidence supporting the likely key pathogenic role of elevated oxidative
stress in PoAF.
Clinical Trial Registration-—URL: Clinicaltrials.gov Unique identifier: NCT00970489. ( J Am Heart Assoc. 2015;4:e001886 doi:
10.1161/JAHA.115.001886)
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P ostoperative atrial fibrillation (PoAF) commonly compli-cates cardiac surgery. PoAF increases the risk of
thromboembolic events, prolongs hospital care, increases
healthcare costs, and elevates long-term mortality.1 Current
frontline therapy such as b-blockers and amiodarone only
partly prevent PoAF, likely reflecting the complex, multifactorial
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pathogenesis of PoAF.2 Improved understanding of the precise
molecular and physiologic mechanisms contributing to PoAF
could promote the development of novel targeted
interventions.
Experimental evidence suggests oxidative stress can con-
tribute to the pathogenesis of PoAF.2 Oxidative stress occurs
when excess production of reactive oxygen species (ROS)
overwhelms endogenous antioxidant defenses, resulting in
tissue injury. In animal studies, oxidative stress contributed to
cardiac myocyte dysfunction, electrical and structural remod-
eling, and the development of AF.3–5 Furthermore, oxidative
stress could potentiate PoAF via activation of stress signaling
pathways and inflammatory responses, which in turn amplify
tissue injury.6,7 Evidence supporting the relationship between
oxidative stress and PoAF in humans, however, remains limited.
Studies based on analyses of human atrial tissues collected
during cardiac surgery suggest a pathogenic role of oxidative
stress and, in particular, identified elevated atrial nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase activity as
associated with PoAF.8,9 Conversely, measurements of circu-
lating oxidative stress biomarkers have yielded mixed find-
ings,9–11 although such studies typically assessed oxidative
stress by using biomarkers with low sensitivity and specificity,
which could obscure potential associations.12 Furthermore,
although levels of oxidative stress vary throughout the
perioperative time course,13 there is a lack of comprehensive
evaluation of the relationship of oxidative stress with PoAF at
different cardiac surgery time points.
To investigate further the role of oxidative stress in PoAF,
we tested the hypothesis that plasma and urine levels of F2-
isoprostanes (F2-isoP), isofurans (IsoF), and F3-isoprostanes
(F3-IsoP) associate with incident PoAF in a subset of 551
subjects in the Omega-3 Fatty Acids for Prevention of Post-
Operative Atrial Fibrillation (OPERA) trial.14 F2-isoP, IsoF, and
F3-IsoP are highly sensitive and robust lipid oxidation
biomarkers derived from arachidonic acid (F2-isoP and IsoF)
and eicosapentaenoic acid (F3-IsoP).
15,16 Concentrations of
these biomarkers were measured at baseline (ie, at study
recruitment, representing baseline ambulatory levels of oxi-
dative stress), at the end of cardiac surgery (reflecting acute
changes in oxidative damage following ischemia–reperfusion),
and again at postoperative day 2 (to capture trends in




This investigation was designed as an ancillary study of the
OPERA trial, which was a randomized, placebo-controlled study
that found perioperative fish oil supplementation did not reduce
PoAF.14 Design of the OPERA study has been reported in detail
previously.17,18 In brief, the study enrolled 1516 patients from
28 medical centers undergoing cardiac surgery in 3 countries
(United States, Italy, and Argentina). The inclusion criteria were
broad: age ≥18 years, presence of sinus rhythm on the
screening electrocardiogram (ECG), and being scheduled for
cardiac surgery on the following day or later. Exclusions were
absence of sinus rhythm at screening, regular use of fish oil,
known intolerance or allergy to fish oil or olive oil (placebo),
unable or unwilling to provide informed consent, being currently
pregnant, or having an existing or a planned cardiac transplant
or use of ventricular assist device. All participants provided
written informed consent, and the study was approved by the
human subjects committees of all participating institutions.
Seventeen study centers participated in this ancillary study.
Oxidative Stress Biomarkers
EDTA-anticoagulated fasting blood and spot urine samples
were collected from subjects with the use of standardized kits
and techniques at baseline, the end of cardiac surgery, and
postoperative day 2. Biologic samples were stored at 70°C
at each study center and subsequently transferred on dry ice
to a central sample bank for long-term storage at 80°C.
After completion of the OPERA study, oxidative stress
biomarkers were measured at the Eicosanoid Core Laboratory
at Vanderbilt University with the use of highly robust and
specific gas chromatography–mass spectrometry.19 Limits of
detection were 1, 5, and 10 pg/mL for F2-IsoP, F3-Iso, and
IsoF, respectively. Interassay coefficient of variations were
≤15%. Levels of oxidative stress biomarkers in plasma are
reported in picograms per milliliter, whereas their levels in
urine are normalized to creatinine clearance and reported as
nanograms per milligrams of creatinine. We were unable to
quantify oxidative stress biomarkers in a small portion of
samples (≤2% for F2-IsoP and IsoF, ≤12% for F3-IsoP) due to
coeluting contaminants, and these samples were thus
excluded from the analyses. If the level of an oxidative stress
biomarker in a sample was less than the assay detection limit,
its value was imputed as half of the detection limit.
Covariates
Other potential risk factors for PoAF were assessed by using
standardized methods including demographics, lifestyle
behaviors, cardiovascular risk factors, anthropometric mea-
surements, medical and surgical history, comorbidities, med-
ication use (outpatient and inpatient), echocardiographic
evaluation, and laboratory measures. Additional data were
collected regarding surgical procedure and daily follow-up and
discharge information.
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Outcomes
A centralized events committee of cardiac electrophysiolo-
gists reviewed and adjudicated all suspected episodes of
PoAF, based on documentations including duration, clinical
information, and confirmatory rhythm strip or 12-lead ECG.
The primary end point for this analysis is incident PoAF of
≥30 seconds’ duration, with outcomes assessed until hospital
discharge or postoperative day 10, whichever occurred first.
Statistical Analysis
The interrelationships between individual oxidative stress
biomarkers were assessed at each time point by using
Spearman correlation coefficients. Changes in biomarker level
between study time points were assessed with paired t test.
Oxidative stress biomarker concentrations were evaluated in
quartiles as indicator variables, and their associations with
incident PoAF were investigated by using multivariable-
adjusted logistic regression. Biomarkers were also examined
as continuous variables after log transformation because these
variables were right-skewed. Tests of linear trend were
conducted by assigning to participants the median value in
each quartile and assessing this as a single continuous
variable. We also examined possible nonlinear relationships
between circulating and urine biomarkers and risk of PoAF
nonparametrically by using restricted cubic splines, after
excluding participants with extreme values (<1st or >99th
percentile) to minimize the effects of outliers. To minimize
confounding, we adjusted for age, sex, country, body mass
index, prevalent hypertension, prevalent diabetes, prevalent
coronary heart disease, prevalent chronic renal failure,
prevalent heart failure, smoking, dyslipidemia, statin medica-
tion use, left ventricular ejection fraction, and logistic Euro-
score.20 Adjustment for treatment did not make a difference
and was not included in the final model. Missing covariates
(<3%) were singly imputed by best-subset-regression with
demographic/risk variables. Results were similar excluding
those with missing covariate values. In sensitivity analyses, we
also assessed the association between changes in oxidative
stress biomarker concentrations from baseline to end of
surgery and PoAF.
Effect modification were evaluated in stratified analyses for
several subgroups including age (<median, ≥median), sex,
country, body mass index (<median, ≥median), type of surgery
(valve surgery versus nonvalve surgery), smoking (current
versus ex-smokers and nonsmokers), aspirin use, and statin
use. For each subgroup, oxidative stress biomarkers were
assessed in stratum-specific quartiles as indicator variables.
The significance of potential effect modification was tested by
using the Wald test for a multiplicative interaction term
between the biomarker quartiles (evaluated as ordinal
variables) and the stratification variable, with Bonferroni-
corrected a level to account for multiple comparisons. All P
values were 2-tailed (a=0.05), and analyses were performed
with Stata 13.1 (Stata Corp).
Results
The mean age of the participants was 63 years, and the
majority (72%) were men (Table). Subjects were enrolled in
the United States (57%), Italy (32%), and Argentina (11%). As
expected, there was a high prevalence of cardiometabolic
risk factors, including hypertension and dyslipidemia, and
nearly 50% of the subjects have a history of coronary heart
disease.
The levels of individual oxidative stress biomarkers and
their correlations are shown in the online supplemental data
(Table S1). While the concentrations of F2-IsoP and IsoF were
similar, they were an order of magnitude larger than F3-Iso in
both plasma and urine. Biomarkers measured in the same
compartment (plasma or urine) showed moderate to high
correlations, with the strongest associations observed for F2-
IsoP and IsoF. For example, Spearman correlation coefficients
at the end of cardiac surgery were between 0.43 and 0.72
among urine oxidative stress biomarkers (P<0.001 for each);
conversely, plasma concentrations of each biomarker corre-
lated either not at all or only weakly with their respective urine
levels. For example, plasma and urine isofurans did not
correlate significantly at any of the time points assessed (r =
0.05 to 0.05, P≥0.32 for each).
There were significant changes in the concentrations of
oxidative stress biomarkers aftert cardiac surgery, with
distinct patterns for plasma and urine measurements, as well
as for subjects who did or did not develop PoAF (Figures 1
and 2). One of the most pronounced change was the 2- to 3-
fold increase over baseline in urine level of all 3 oxidative
stress biomarkers following cardiac surgery (P<0.001 for
each). Furthermore, at the end of surgery, F2-isoP and IsoF
levels were 20% and 50% higher in subjects who
subsequently developed PoAF (P≤0.009, adjusted for enroll-
ment biomarker concentrations). At postoperative day 2, urine
levels of all 3 biomarkers fell significantly (paired t test
relative to end of surgery, P≤0.03 for each), to concentrations
comparable to baseline. Plasma levels of oxidative stress
biomarkers did not show such marked variation as urine
concentrations throughout the study. At postoperative day 2,
levels of F2-IsoP and IsoF were slightly lower relative to the
end of surgery (10%, P≤0.04 for each), and F2-IsoP levels
were 20% higher in subjects who developed PoAF than in
those who did not (P=0.05). Plasma F3-Iso was higher at the
end of cardiac surgery (40%, P<0.001) and remained similar
at postoperative day 2.
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Among the 551 subjects in the study, 171 developed PoAF
during follow-up. Oxidative stress biomarkers in plasma or
urine at baseline did not associate significantly with PoAF
(online supplemental data, Tables S2 and S3). By the end of
surgery, however, the concentrations of IsoF in urine and
plasma associated with elevated risk of PoAF. For example,
the OR (95% CI) for participants in the highest compared with
the lowest quartile of urine IsoF was 1.95 (1.05 to 3.62, P for
trend=0.01). Urine, but not plasma F3-IsoP, concentration also
associated with higher PoAF risk, with extreme quartile OR
(95% CI) of 2.10 (1.04 to 2.25, P for trend=0.04). F2-IsoP at
the end of surgery did not associate with PoAF. At
postoperative day 2, plasma F2-IsoP and IsoF both associated
with higher PoAF risk, with extreme quartile OR (95% CI) of
2.53 (1.14 to 5.58) and 2.98 (1.22 to 7.25), respectively.
Urine concentrations of these biomarkers did not significantly
Table. Baseline Characteristics of Subjects With Oxidative







Sex, % male 72.2
Planned valve surgery, % 55.0
Planned CABG, % 48.3
Current smoking, % 13.3
Diabetes mellitus, % 29.8




Chronic renal failure, % 6.5
Coronary heart disease, % 44.5
Prior myocardial infarction, % 22.9
Prior PCI, % 14.5
Prior arrhythmias, % 13.8
Prior atrial fibrillation, % 8.0
Congestive heart failure, % 20.0
Ejection fraction, % 56.211.2
b-Blocker, % 54.1
Statins, % 56.6
ACE inhibitor, % 35.6
Aspirin, % 61.9
Antiarrhythmics, % 4.4
Logistic Euroscore, units 6.27.5
CABG indicates coronary artery bypass graft surgery; COPD, chronic obstructive
pulmonary disease; PCI, percutaneous coronary intervention; ACE, angiotensin-
converting enzyme.
*Values are meanSD for continuous variables, and percent for categorical variables.
Figure 1. Plasma oxidative stress biomarkers concentration
(pg/mL) at baseline (recruitment), end of surgery (at time of
closure), and postoperative day 2. Data shown are meanSE. The
white and gray bars represent subjects without and with incident
postoperative atrial fibrillation (PoAF), respectively. *Mean plasma
level of F2-isoprostanes were 20% higher in patients who
developed PoAF than in those who did not (P=0.05, adjusted for
end of surgery F2-isoprostane concentrations).
Figure 2. Urine creatinine-adjusted concentration of oxidative
stress biomarkers (ng/mg) at baseline (recruitment), end of
surgery (at time of closure), and postoperative day 2. Data shown
are meanSE. The white and gray bars represent subjects
without and with incident postoperative atrial fibrillation (PoAF),
respectively. *Mean urine F2-isoprostane and isofuran levels were
20% and 50% higher in subjects who subsequently developed
PoAF (P≤0.009, adjusted for baseline concentrations).
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associate with PoAF. Similarly, levels of F3-IsoP at postop-
erative day 2 in urine and plasma were not associated with
subsequent PoAF. Semiparametric analyses with restricted
cubic splines suggested relatively linear (monotonic) asso-
ciations of oxidative stress biomarkers at the end of
surgery and postoperative day 2 with incident PoAF
(Figures 3 and 4).
Results were similar when the biomarkers were assessed
continuously. For example, each doubling of urine IsoF at the
end of surgery was associated with an OR (95% CI) of 1.20
(1.03 to 1.41, P=0.02). In sensitivity analyses, changes in
plasma and urine oxidative stress biomarker concentration
from baseline to the end of surgery showed similar direction
and magnitude of association with PoAF as end of surgery
levels alone (not shown). Further adjustment for study
treatment, valve surgery, time on pump, prevalent obstructive
pulmonary disease, antiarrhythmic medication, changes in
white blood cell count, and aspirin use did not appreciably
alter the results (not shown). There was little evidence that
country, age, sex, body mass index, type of surgery, smoking,
A
B C
Figure 3. Multivariable-adjusted association of plasma (A) isofuran at end of surgery (B) isofuran at postoperative day 2 and (C)
F2-isoprostanes at postoperative day 2 with postoperative atrial fibrillation (PoAF), evaluated by restricted cubic splines and logistic regression.
Biomarkers underwent log-transformation before analyses as they were right-skewed, and analyses adjusted for age (years), sex (male/female),
country (US, Italy, Argentina), body mass index (kg/m2), prevalent hypertension (yes/no), prevalent diabetes (yes/no), prevalent coronary heart
disease (yes/no), prevalent chronic renal failure (yes/no), prevalent heart failure (yes/no), smoking (never or former/current), dyslipidemia
(yes/no), statin medication use (yes/no), ejection fraction (%), and logistic Euroscore (continuous). The solid red line and shaded areas
represent the OR and 95% CIs, respectively, in comparison to the reference level representing the median value of the lowest quartile (12.5th
percentile). Dotted vertical lines correspond to the 10th, 25th, 50th, 75th, and 90th percentiles of the log biomarker concentrations. There was
overall linear association for each biomarkers with PoAF (P≤0.02) but little evidence of nonlinearity (P≥0.83).
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and aspirin and statin use significantly modified the
association of oxidative stress biomarkers and PoAF (Bonfer-
roni corrected, P for interaction ≥0.29 for each).
Discussion
In this prospective cohort study of cardiac surgery patients,
higher end of surgery and postoperative oxidative stress
assessed by F2-IsoP, IsoF, and F3-IsoP associated
independently with elevated risk of PoAF. The magnitude of
associations was substantial, and subjects in the top quartile
of lipid peroxidation biomarker had up to 3-fold higher odds of
PoAF. In contrast, baseline IsoP and IsoF did not associate
with PoAF.
Accumulating experimental evidence supports the biologic
plausibility of these findings by indicating a causal role of
oxidative stress in pathologic atrial structural remodeling,
abnormal ion channel function, and increased vulnerability to
AF.21 In animals, risk factors for AF development, such as
hypertension and heart failure, link with increased ROS
production,22,23 and treatment with antioxidants reduces
atrial fibrosis and prevents tissue oxidative damage and
occurrence of AF.24–26 Arachidonic acid and eicosapentaenoic
acids in cardiac membranes may also influence AF develop-
ment.27 Structural modification of these polyunsaturated fatty
acids by ROS to IsoP and IsoF may disrupt their capacity to
regulate protein and ion channel functions.28 Furthermore,
not only do IsoP and IsoF serve as sensitive biomarkers of
oxidative stress in vivo; they also may contribute to inflam-
mation, such as by enhancing adhesion of monocytes to
endothelial cells.29,30
The observed increase in urine F2-IsoP, IsoF, and F3-IsoP
between baseline and the end of surgery is consistent with
cardiac surgery–induced oxidative stress.31 Our data also
indicate the transience of the imbalance in ROS generation
and antioxidant defense triggered by cardiac surgery, as levels
of urine biomarkers fell to near baseline levels by postoper-
ative day 2. Whereas urine levels of these oxidative stress
biomarkers provide a time-integrated measure of subacute
systemic oxidative stress, their plasma levels reflect acute
systemic oxidative stress, due to their rapid metabolism and
renal excretion,32 which may explain the relative stability of
plasma levels of these biomarkers observed in our study.
Urine IsoF demonstrated a relatively greater increase than
IsoP. Although both IsoF and IsoP arise from ROS-mediated
peroxidation of polyunsaturated fatty acids, mitochondrial
dysfunction and elevated oxygen concentration favor forma-
tion of IsoF.16 Our results, therefore, highlight the likely
importance of identifying not only endogenous sources of
oxidative stress but also factors that expose patients to
increased oxygen concentration, such as inspired oxygen
supplementation during cardiac surgery.
Our investigation demonstrates that higher oxidative stress
at postoperative day 2 associates with subsequent risk of
PoAF. These findings highlight the need to identify therapies
that could reduce oxidative stress throughout the perioper-
ative time course, specifically targeting oxidants that may
cause lipid oxidation. Increasing evidence suggest both
statins, which downregulate NADPH oxidase,33 and antioxi-
dant scavengers are of potential interest, and recent meta-
analyses of controlled trials found supplementation with
A
B
Figure 4. Multivariable-adjusted association of end of surgery
(A) urine isofurans and (B) urine F3-isoprostanes with postoper-
ative atrial fibrillation (PoAF), evaluated by restricted cubic splines
and logistic regression. Biomarkers underwent log-transformation
before analyses as they were right-skewed, and analyses adjusted
for age (years), sex (male/female), country (US, Italy, Argentina),
body mass index (kg/m2), prevalent hypertension (yes/no),
prevalent diabetes (yes/no), prevalent coronary heart disease
(yes/no), prevalent chronic renal failure (yes/no), prevalent heart
failure (yes/no), smoking (never or former/current), dyslipidemia
(yes/no), statin medication use (yes/no), ejection fraction (%),
and logistic Euroscore (continuous). The solid red line and shaded
areas represent the OR and 95% CIs, respectively, in comparison
to the reference level representing the median value of the lowest
quartile (12.5th percentile). Dotted vertical lines correspond to
the 10th, 25th, 50th, 75th, and 90th percentiles of the log
biomarker concentrations. Both biomarkers associated linearly
overall with PoAF (P=0.02 for each) but showed little evidence of
nonlinearity (P≥0.26 for each).
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statins or putative antioxidants (eg, vitamin C) reduced the
risk of PoAF.34,35 However, these findings should be inter-
preted with caution given the large heterogeneity observed
between the results of individual trials and the lack of
evidence that the treatments actually reduced oxidative stress
in vivo.35 Our findings indicate that future trials could
rationally determine the dose and duration of statin or
antioxidant therapy for PoAF prevention, based on their ability
to reduce plasma or urine IsoP and IsoF. Because oxidative
stress may activate inflammation, future studies should also
examine inflammatory biomarkers (eg, myeloperoxidase),
which could provide additional information.6,36
Our study has important strengths. The use of highly
sensitive and specific IsoP and IsoF, assessed across
multiple perioperative time points allowed comprehensive
evaluation of the relationships of lipid oxidation and PoAF,
and inclusion of these complementary biomarkers provide
additional insight into potential oxidative stress mechanisms.
The study used highly accurate and reproducible assays to
measure the biomarkers, limiting the likelihood of misclas-
sification of these exposures. The prospective design min-
imized selection bias and enabled inference on temporality
of associations. Careful collection of information on many
potential covariates allowed detailed adjustment to control
for confounding. A centralized events committee conducted
careful adjudication of PoAF events that lowered the
possibility of outcome misclassification. Subjects in the
OPERA trial were from different countries with varied
demographic and lifestyle characteristics, which enhances
generalizability.
Potential limitations also merit consideration. While IsoP
and IsoF quantify the extent of lipid peroxidation, they do not
provide insight into oxidative damage to other cellular
compartments such as proteins and DNA, and these should
be assessed in the future by using other validated biomarkers.
We adjusted for a range of important demographic and clinical
risk factors, but we cannot exclude the possibility of residual
confounding due to unmeasured or imprecisely measured
factors. Only a subset of OPERA trial subjects participated in
this biologic study, which reduced statistical power. Never-
theless, this current investigation represents by far the largest
study assessing objective, validated oxidative stress biomar-
kers in cardiac surgery patients. Although results from this
study are relevant to cardiac surgery patients, findings may
not be applicable to other populations at risk of AF. Of course,
the strong association demonstrated by these data cannot
establish causality between oxidative stress and the advent of
PoAF. Yet, the grounds for biological plausibility mentioned
here do support a causal link between oxidative stress and
PoAF. Finally, our findings suggest the need to carefully
evaluate the effect of fish oil treatment on oxidative stress
levels in future studies.
In summary, cardiac surgery induce acute increase in
oxidative stress as assessed with urine levels of IsoP and IsoF.
In addition, elevated end of surgery and postoperative levels
of these oxidative stress biomarkers relate to higher risk of
PoAF. These novel results adds to growing evidence support-
ing the likely key pathogenic role of elevated oxidative stress
in PoAF and suggest that further development of therapies
targeting oxidative stress pathways for the prevention of PoAF
is warranted.
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Supplement Table 1: Concentrations and Unadjusted Spearman Correlation Coefficients for Plasma and Urine 



















Baseline       
Concentration, mean±SD 51.7±38.2 2.7±4.2 62.5±98.5 1.36±0.89 0.19±1.30 1.89±1.26 
Plasma F2-isoprostanes 1.00      
Plasma F3-isoprostanes 0.33* 1.00     
Plasma isofuran 0.52* 0.28* 1.00    
Urine F2-isoprostanes 0.18* 0.10* -0.08 1.00   
Urine F3-isoprostanes 0.02 0.25* -0.08 0.37* 1.00  
Urine isofurans 0.10* 0.11* -0.05 0.51* 0.43* 1.00 
End of surgery       
Concentration, mean±SD 50.6±52.9 3.9±5.6 66.7±73.6 4.13±4.60 0.58±1.46 7.12±10.96 
Plasma F2-isoprostanes 1.00      
Plasma F3-isoprostanes 0.38* 1.00     
Plasma isofuran 0.61* 0.32* 1.00    
Urine F2-isoprostanes 0.12* -0.05 0.04 1.00   
Urine F3-isoprostanes -0.01 0.28* -0.11* 0.48* 1.00  
Urine isofurans -0.003 -0.06 -0.02 0.72* 0.43* 1.00 
Post-op day 2       
Concentration, mean±SD 45.6±37.0 4.0±7.2 55.3±66.3 1.63±1.20 0.40±0.87 2.50±2.16 
Plasma F2-isoprostanes 1.00      
Plasma F3-isoprostanes 0.34* 1.00     
Plasma isofuran 0.60* 0.31* 1.00    
Urine F2-isoprostanes 0.18* 0.12* 0.13* 1.00   
Urine F3-isoprostanes 0.08 0.37* 0.04 0.42* 1.00  




Supplementary Table 2. Multivariable-Adjusted Risk of Post-Operative Atrial Fibrillation According to Plasma 
Oxidative Stress Biomarkers in the OPERA Trial* 
 Quartiles of Oxidative Stress Biomarkers  
 1st 2nd 3rd 4th P for trend† 
Baseline concentrations      
F2-isoprostanes      
Concentration (pg/mL) 25.5±6.4 38.2±3.1 49.2±3.7 95.2±55.3  
No. of cases/n 46/138 52/145 37/132 36/136  
Odds ratio (95% CI) 1.0 (reference) 1.01 (0.60-1.69) 0.66 (0.38-1.15) 0.72 (0.40-1.32) 0.21 
Isofurans      
Concentration (pg/mL) 20.8±5.7 33.8±3.1 46.9±4.8 151±170  
No. of cases/n 45/135 34/137 40/135 48/132  
Odds ratio (95% CI) 1.0 (reference) 0.59 (0.33-1.04) 0.84 (0.48-1.47) 1.31 (0.74-2.33) 0.08 
F3-isoprostanes      
Concentration (pg/mL) 0.5±0.0 1.0±0.1 2.4±0.5 7.5±6.4  
No. of cases/n‡ 61/220 17/59 42/132 48/130  
Odds ratio (95% CI) 1.0 (reference) 0.97 (0.50-1.91) 1.23 (0.75-2.02) 1.39 (0.85-2.25) 0.16 
End of surgery concentrations      
F2-isoprostanes      
Concentration (pg/mL) 22.6±4.8 34.1±2.9 47.2±4.9 100±88.4  
No. of cases/n 45/142 46/131 38/139 48/134  
Odds ratio (95% CI) 1.0 (reference) 1.02 (0.60-1.74) 0.75 (0.43-1.31) 1.51 (0.83-2.73) 0.16 
Isofurans      
Concentration (pg/mL) 24.9±7.1 42.9±4.4 61.2±6.7 139±118  
No. of cases/n‡ 40/138 40/133 42/129 52/133  
Odds ratio (95% CI) 1.0 (reference) 1.18 (0.68-2.06) 1.18 (0.67-2.09) 1.85 (1.04-3.30) 0.03 
F3-isoprostanes      
Concentration (pg/mL) 0.5±0.0 1.6±0.5 3.6±0.8 11.1±7.9  
No. of cases/n‡ 54/158 36/127 46/129 38/123  
Odds ratio (95% CI) 1.0 (reference) 0.79 (0.46-1.37) 1.00 (0.59-1.70) 0.86 (0.50-1.47) 0.70 
Post-op day 2 concentrations§      
F2-isoprostanes      
Concentration (pg/mL) 21.6±4.9 31.8±2.6 42.8±4.2 78.8±41.7  
No. of cases/n 14/105 17/103 14/104 25/102  
Odds ratio (95% CI) 1.0 (reference) 1.14 (0.50-2.59) 1.15 (0.49-2.71) 2.53 (1.14-5.58) 0.01 
Isofurans      
Concentration (pg/mL) 19.6±6.1 32.6±3.2 46.3±5.4 118±98.0  
No. of cases/n 11/101 14/101 24/102 20/99  
Odds ratio (95% CI) 1.0 (reference) 1.57 (0.63-3.91) 3.07 (1.29-7.31) 2.98 (1.22-7.25) 0.02 
F3-isoprostanes      
Concentration (pg/mL) 0.5±0.0 1.6±0.5 3.2±0.6 12.1±12.0  
No. of cases/n‡ 23/138 13/87 18/86 16/93  
Odds ratio (95% CI) 1.0 (reference) 0.77 (0.34-1.72) 1.02 (0.48-2.16) 0.92 (0.43-1.96) 0.93 
* Adjusted for age (years), gender (male/female), country(Italy, USA, Argentina), body mass index (kg/m2), prevalent hypertension 
(yes/no), prevalent diabetes (yes/no), prevalent coronary heart disease (yes/no), prevalent chronic renal failure (yes/no), prevalent heart 
failure (yes/no), smoking (never or former/current), dyslipidemia (yes/no), statin medication use (yes/no), ejection fraction (%), and 
logistic Euroscore (continuous). 
† Linear trend was tested by assigning to participants the median value in each quartile and assessing this as a continuous variable.  All 
findings were similar when biomarker concentrations were evaluated in their natural units as continuous exposures. 
‡ Bottom quartile consisted of subjects whose plasma F3-Isoprostanes were below the detection limit.   
§ Excluding subjects who developed PoAF within two days of surgery for these analyses.  
  
Supplementary Table 3. Multivariable-Adjusted Risk of Post-Operative Atrial Fibrillation According to Creatinine 
Adjusted Urine Oxidative Stress Biomarkers in the OPERA Trial* 
 Quartiles of Oxidative Stress Biomarkers  
 1st 2nd 3rd 4th P for trend† 
 Baseline concentrations      
F2-isoprostanes      
Concentration (ng/mg) 0.53±0.17 0.97±0.11 1.38±0.14 2.57±0.89  
No. of cases/n 44/129 43/134 32/122 32/128  
Odds ratio (95% CI) 1.0 (reference) 0.93 (0.54-1.59) 0.69 (0.39-1.22) 0.79 (0.44-1.43) 0.35 
Isofurans      
Concentration (ng/mg) 0.77±0.27 1.36±0.16 1.94±0.18 3.51±1.43  
No. of cases/n 36/129 36/126 39/128 40/127  
Odds ratio (95% CI) 1.0 (reference) 1.05 (0.59-1.87) 1.08 (0.60-1.94) 1.49 (0.82-2.72) 0.16 
F3-isoprostanes      
Concentration (ng/mg) 0.01±0.005 0.06±0.02 0.13±0.02 0.58±2.59  
No. of cases/n 33/116 26/115 41/116 38/114  
Odds ratio (95% CI) 1.0 (reference) 0.56 (0.28-1.11) 1.21 (0.63-2.30) 1.11 (0.57-2.17) 0.23 
End of surgery concentrations      
F2-isoprostanes      
Concentration (ng/mg) 1.10±0.37 2.15±0.35 3.63±0.57 9.64±6.38  
No. of cases/n 38/128 34/126 46/127 45/127  
Odds ratio (95% CI) 1.0 (reference) 0.75 (0.42-1.34) 1.39 (0.78-2.47) 1.26 (0.69-2.30) 0.20 
Isofurans      
Concentration (ng/mg) 1.45±0.54 3.01±0.53 5.41±1.04 18.6±17.2  
No. of cases/n 35/128 38/127 41/127 50/127  
Odds ratio (95% CI) 1.0 (reference) 1.02 (0.57-1.85) 1.19 (0.66-2.14) 1.95 (1.05-3.62) 0.01 
F3-isoprostanes      
Concentration (ng/mg) 0.01±0.02 0.15±0.05 0.37±0.10 1.80±2.56  
No. of cases/n 29/114 32/113 42/114 42/113  
Odds ratio (95% CI) 1.0 (reference) 1.17 (0.59-2.31) 1.87 (0.94-3.71) 2.10 (1.04-4.25) 0.04 
Post-op day 2 concentrations‡      
F2-isoprostanes      
Concentration (ng/mg) 0.57±0.23 1.10±0.11 1.67±0.23 3.28±1.29  
No. of cases/n 16/97 13/96 16/96 17/96  
Odds ratio (95% CI) 1.0 (reference) 0.91 (0.39-2.16) 1.36 (0.59-3.14) 1.26 (0.53-3.01) 0.48 
Isofurans      
Concentration (ng/mg) 0.92±0.27 1.60±0.21 2.42±0.30 5.04±3.0  
No. of cases/n 12/98 16/95 16/96 18/96  
Odds ratio (95% CI) 1.0 (reference) 1.31 (0.53-3.22) 1.25 (0.50-3.13) 1.23 (0.48-3.17) 0.83 
F3-isoprostanes      
Concentration (ng/mg) 0.02±0.02 0.10±0.03 0.22±0.06 1.14±1.17  
No. of cases/n 8/87 14/86 22/87 15/86  
Odds ratio (95% CI) 1.0 (reference) 1.94 (0.70-5.41) 2.92 (1.10-7.80) 1.76 (0.59-5.24) 0.90 
* Adjusted for age (years), gender (male/female), country(Italy, USA, Argentina), body mass index (kg/m2), prevalent hypertension 
(yes/no), prevalent diabetes (yes/no), prevalent coronary heart disease (yes/no), prevalent chronic renal failure (yes/no), prevalent heart 
failure (yes/no), smoking (never or former/current), dyslipidemia (yes/no), statin medication use (yes/no), ejection fraction (%), and 
logistic Euroscore (continuous). 
† Linear trend was tested by assigning to participants the median value in each quartile and assessing this as a continuous variable.  All 
findings were similar when biomarker concentrations were evaluated in their natural units as continuous exposures. 
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Plasma F2-isoprostanes 1.00      
Plasma F3-isoprostanes 0.33* 1.00     
Plasma isofuran 0.52* 0.28* 1.00    
Urine F2-isoprostanes 0.18* 0.10* -0.08 1.00   
Urine F3-isoprostanes 0.02 0.25* -0.08 0.37* 1.00  
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Plasma F2-isoprostanes 1.00      
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Plasma isofuran 0.61* 0.32* 1.00    
Urine F2-isoprostanes 0.12* -0.05 0.04 1.00   
Urine F3-isoprostanes -0.01 0.28* -0.11* 0.48* 1.00  
Urine isofurans -0.003 -0.06 -0.02 0.72* 0.43* 1.00 
Post-op day 2       
Concentration, mean±SD 45.6±37.0 4.0±7.2 55.3±66.3 1.63±1.20 0.40±0.87 2.50±2.16 
Plasma F2-isoprostanes 1.00      
Plasma F3-isoprostanes 0.34* 1.00     
Plasma isofuran 0.60* 0.31* 1.00    
Urine F2-isoprostanes 0.18* 0.12* 0.13* 1.00   
Urine F3-isoprostanes 0.08 0.37* 0.04 0.42* 1.00  
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Oxidative Stress Biomarkers in the OPERA Trial* 
 Quartiles of Oxidative Stress Biomarkers  
 1st 2nd 3rd 4th P for trend† 
Baseline concentrations      
F2-isoprostanes      
Concentration (pg/mL) 25.5±6.4 38.2±3.1 49.2±3.7 95.2±55.3  
No. of cases/n 46/138 52/145 37/132 36/136  
Odds ratio (95% CI) 1.0 (reference) 1.01 (0.60-1.69) 0.66 (0.38-1.15) 0.72 (0.40-1.32) 0.21 
Isofurans      
Concentration (pg/mL) 20.8±5.7 33.8±3.1 46.9±4.8 151±170  
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Odds ratio (95% CI) 1.0 (reference) 0.59 (0.33-1.04) 0.84 (0.48-1.47) 1.31 (0.74-2.33) 0.08 
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Concentration (pg/mL) 0.5±0.0 1.0±0.1 2.4±0.5 7.5±6.4  
No. of cases/n‡ 61/220 17/59 42/132 48/130  
Odds ratio (95% CI) 1.0 (reference) 0.97 (0.50-1.91) 1.23 (0.75-2.02) 1.39 (0.85-2.25) 0.16 
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Concentration (pg/mL) 22.6±4.8 34.1±2.9 47.2±4.9 100±88.4  
No. of cases/n 45/142 46/131 38/139 48/134  
Odds ratio (95% CI) 1.0 (reference) 1.02 (0.60-1.74) 0.75 (0.43-1.31) 1.51 (0.83-2.73) 0.16 
Isofurans      
Concentration (pg/mL) 24.9±7.1 42.9±4.4 61.2±6.7 139±118  
No. of cases/n‡ 40/138 40/133 42/129 52/133  
Odds ratio (95% CI) 1.0 (reference) 1.18 (0.68-2.06) 1.18 (0.67-2.09) 1.85 (1.04-3.30) 0.03 
F3-isoprostanes      
Concentration (pg/mL) 0.5±0.0 1.6±0.5 3.6±0.8 11.1±7.9  
No. of cases/n‡ 54/158 36/127 46/129 38/123  
Odds ratio (95% CI) 1.0 (reference) 0.79 (0.46-1.37) 1.00 (0.59-1.70) 0.86 (0.50-1.47) 0.70 
Post-op day 2 concentrations§      
F2-isoprostanes      
Concentration (pg/mL) 21.6±4.9 31.8±2.6 42.8±4.2 78.8±41.7  
No. of cases/n 14/105 17/103 14/104 25/102  
Odds ratio (95% CI) 1.0 (reference) 1.14 (0.50-2.59) 1.15 (0.49-2.71) 2.53 (1.14-5.58) 0.01 
Isofurans      
Concentration (pg/mL) 19.6±6.1 32.6±3.2 46.3±5.4 118±98.0  
No. of cases/n 11/101 14/101 24/102 20/99  
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* Adjusted for age (years), gender (male/female), country(Italy, USA, Argentina), body mass index (kg/m2), prevalent hypertension 
(yes/no), prevalent diabetes (yes/no), prevalent coronary heart disease (yes/no), prevalent chronic renal failure (yes/no), prevalent heart 
failure (yes/no), smoking (never or former/current), dyslipidemia (yes/no), statin medication use (yes/no), ejection fraction (%), and 
logistic Euroscore (continuous). 
† Linear trend was tested by assigning to participants the median value in each quartile and assessing this as a continuous variable.  All 
findings were similar when biomarker concentrations were evaluated in their natural units as continuous exposures. 
‡ Bottom quartile consisted of subjects whose plasma F3-Isoprostanes were below the detection limit.   
§ Excluding subjects who developed PoAF within two days of surgery for these analyses.  
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Odds ratio (95% CI) 1.0 (reference) 0.93 (0.54-1.59) 0.69 (0.39-1.22) 0.79 (0.44-1.43) 0.35 
Isofurans      
Concentration (ng/mg) 0.77±0.27 1.36±0.16 1.94±0.18 3.51±1.43  
No. of cases/n 36/129 36/126 39/128 40/127  
Odds ratio (95% CI) 1.0 (reference) 1.05 (0.59-1.87) 1.08 (0.60-1.94) 1.49 (0.82-2.72) 0.16 
F3-isoprostanes      
Concentration (ng/mg) 0.01±0.005 0.06±0.02 0.13±0.02 0.58±2.59  
No. of cases/n 33/116 26/115 41/116 38/114  
Odds ratio (95% CI) 1.0 (reference) 0.56 (0.28-1.11) 1.21 (0.63-2.30) 1.11 (0.57-2.17) 0.23 
End of surgery concentrations      
F2-isoprostanes      
Concentration (ng/mg) 1.10±0.37 2.15±0.35 3.63±0.57 9.64±6.38  
No. of cases/n 38/128 34/126 46/127 45/127  
Odds ratio (95% CI) 1.0 (reference) 0.75 (0.42-1.34) 1.39 (0.78-2.47) 1.26 (0.69-2.30) 0.20 
Isofurans      
Concentration (ng/mg) 1.45±0.54 3.01±0.53 5.41±1.04 18.6±17.2  
No. of cases/n 35/128 38/127 41/127 50/127  
Odds ratio (95% CI) 1.0 (reference) 1.02 (0.57-1.85) 1.19 (0.66-2.14) 1.95 (1.05-3.62) 0.01 
F3-isoprostanes      
Concentration (ng/mg) 0.01±0.02 0.15±0.05 0.37±0.10 1.80±2.56  
No. of cases/n 29/114 32/113 42/114 42/113  
Odds ratio (95% CI) 1.0 (reference) 1.17 (0.59-2.31) 1.87 (0.94-3.71) 2.10 (1.04-4.25) 0.04 
Post-op day 2 concentrations‡      
F2-isoprostanes      
Concentration (ng/mg) 0.57±0.23 1.10±0.11 1.67±0.23 3.28±1.29  
No. of cases/n 16/97 13/96 16/96 17/96  
Odds ratio (95% CI) 1.0 (reference) 0.91 (0.39-2.16) 1.36 (0.59-3.14) 1.26 (0.53-3.01) 0.48 
Isofurans      
Concentration (ng/mg) 0.92±0.27 1.60±0.21 2.42±0.30 5.04±3.0  
No. of cases/n 12/98 16/95 16/96 18/96  
Odds ratio (95% CI) 1.0 (reference) 1.31 (0.53-3.22) 1.25 (0.50-3.13) 1.23 (0.48-3.17) 0.83 
F3-isoprostanes      
Concentration (ng/mg) 0.02±0.02 0.10±0.03 0.22±0.06 1.14±1.17  
No. of cases/n 8/87 14/86 22/87 15/86  
Odds ratio (95% CI) 1.0 (reference) 1.94 (0.70-5.41) 2.92 (1.10-7.80) 1.76 (0.59-5.24) 0.90 
* Adjusted for age (years), gender (male/female), country(Italy, USA, Argentina), body mass index (kg/m2), prevalent hypertension 
(yes/no), prevalent diabetes (yes/no), prevalent coronary heart disease (yes/no), prevalent chronic renal failure (yes/no), prevalent heart 
failure (yes/no), smoking (never or former/current), dyslipidemia (yes/no), statin medication use (yes/no), ejection fraction (%), and 
logistic Euroscore (continuous). 
† Linear trend was tested by assigning to participants the median value in each quartile and assessing this as a continuous variable.  All 
findings were similar when biomarker concentrations were evaluated in their natural units as continuous exposures. 
‡Excluding subjects who developed PoAF within two days of surgery.  
 
 
 
